Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
| العنوان: | Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan |
|---|---|
| المؤلفون: | Sheng-Shun Yang, Chi Wei Tseng, Chien-Ching Hung, Ching Chu Lo, Ming-Chang Tsai, Chun Chao Chang, Jia-Horng Kao, Chi Yang Chang, Chung Hsin Chang, Yu Jen Fang, Chia Sheng Huang, Ke Jhang Huang, Tsai‐Yuan ‐Y Hsieh, Cheng Yuan Peng, Hsueh Chou Lai, Pei Lun Lee, Wei Wen Su, Po-Yueh Chen, Chen-Hua Liu, Chi Yi Chen, Jow Jyh Huang, Yi Jie Huang, Wei-Yu Kao, Chun-Jen Liu, Kuo Chih Tseng, Jyh Jou Chen, Pei Yuan Su, Fu Jen Lee, Yu-Lueng Shih |
| المصدر: | Hepatology International. 15:338-349 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, Nausea, Hepatitis C virus, medicine.disease_cause, Gastroenterology, Sofosbuvir/velpatasvir, Confidence interval, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Cohort, Medicine, 030211 gastroenterology & hepatology, medicine.symptom, business, Adverse effect, medicine.drug |
| الوصف: | Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) for East Asian patients with chronic hepatitis C virus (HCV) infection and compensated liver disease are limited. We evaluated the performance of SOF/VEL for 12 weeks for HCV-infected patients with compensated liver disease in a large real-world cohort in Taiwan. Between July 2019 and March 2020, 1880 HCV-infected patients with compensated liver disease who received SOF/VEL 400/100 mg once daily for 12 weeks were included at 15 academic centers in Taiwan. The sustained virologic response at off-treatment week 12 (SVR12) was assessed for evaluable (EP) and per-protocol populations (PP). The tolerance was also reported. The SVR12 rates by EP and PP analyses were 95.6% [1798 of 1880 patients; 95% confidence interval (CI) 94.6–96.5%] and 99.3% (1798 of 1811 patients; 95% CI 98.8–99.6%), respectively. Among 82 patients who failed to achieve SVR12, 13 (15.9%) were attributed to virologic failures. The SVR12 rates were comparable regardless of baseline characteristics. A total of 1859 (98.9%) patients completed 12-week SOF/VEL treatment. Four (0.2%) patients discontinued treatment due to adverse events (AEs). All patients with serious AEs or deaths were judged not related to SOF/VEL. The AEs occurring in ≥ 10% included headache (16.8%), fatigue (16.2%), nausea (11.8%), and insomnia (11.1%). Nine (0.5%) and 2 (0.1%) patients had grade 3 total bilirubin and alanine aminotransferase elevations. SOF/VEL for 12 weeks is efficacious and well-tolerated by chronic HCV-infected patients with compensated liver disease in Taiwan. |
| تدمد: | 1936-0541 1936-0533 |
| DOI: | 10.1007/s12072-021-10158-x |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::06ef0d14ab5bc903444da29fd7dd467e https://doi.org/10.1007/s12072-021-10158-x |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi...........06ef0d14ab5bc903444da29fd7dd467e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19360541 19360533 |
|---|---|
| DOI: | 10.1007/s12072-021-10158-x |